WHAT DOES ABACTERIAL PROSTATITITS HIDE?

Introduction. It seems 90% of chronic prostatitis (CP) is abacterial, but is it true? The propose is – to estimate a spectrum of chronic abacterial prostatitis and estimate efficiency of complex treatment.

Materials and Methods. Fifty six patients with chronic abacterial prostatitis 3-a category were enrolled in this study: first group (28 patients) received standard treatment and additionally - panavir, and second group (also 28 patients) - standard treatment only. All patients were examined by standard approach, including polimerase chain reaction on intracellular pathogens. Complex therapy was unique and included: doxiciclin, famcyclovir, pathogenetic therapy. Efficiency was estimated by NIH-CPSI scale and by eradication of pathogens.

Results. All patients had chronic abacterial prostatitis 3-a category. Followed pathogens were revealed: Chlamydia trachomatis (17 patients), Ureaplasma urealyticum (15 patients), Mycoplasma genitalium (22 patients), virus Herpes (9 patients). These pathogens formally are not etiological factor, but in fact they maintain inflammation in the prostate. M. tuberculosis was not found. In first group total scores decreased from 20.9 to 7.9, in second group - from 20.8 to 16.3). In three months, pathogens were 17.8% patients больных in first group, and in 42.8% in second group; accordingly efficiency of standard treatment was 57,2%, and in combination with panavir – 82.2%.

onclusion. Examination on intracellular pathogens as well as viruses is indicated for patients with chronic abacterial prostatitis 3-a category. Standard therapy in cobination with panavir significantly imorives results of the treatment. Low efficiency of standard therapy may be explained both by secondary immunodefficiency and by myofascial syndrome.

1. Korneev IA, Alekseeva TA, Kogan MI, Pushkar’ DYu. Epidemiology of urinary disorders in men in the Russian FederaƟ on. Urologiia. 2016;(2S):70-75. (In Russ.).

2. Kulchavenya EV, Kholtobin DP, Shevchenko SYu, Potapov VV, Zulin YaV. The frequency of the chronic prostatitis in the outpatient practice. Eksperimental’naya i klinicheskaya urologiya. 2015;1:16-18. (in Russ.)

3. Heras-Cañas V, Gutiérrez-Soto B, Almonte-Fernández H, Lara-Oya A, Navarro-Marí JM, et al. Antibiotic activity and concentrations in clinical samples from patients with chronic bacterial prostatitis. Actas Urol Esp. 2017;pii: S0210-4806(17)30089-X. doi: 10.1016/j. acuro.2017.03.008.

4. Naber KG, Bergman B, Bishop MC. EAU Guidelines on urinary and male genital tract infections. 2002:49-55.

5. Naboka YuL, Gudima IA, Ibishev XS, Miroshnichenko EA, Kogan MI, Vasil’eva LI. Etiological structure and antibioc sensitivity of uropathogens in chronic recurrent infection of the lower urinary tract. Urologiya. 2011;(6):12-15. (in Russ.)

6. Cai T, Bartoleƫ R. Re: Park et al. The Presence of Chlamydia Is Associated With Increased Leukocyte Counts and Pain Severity in Men With Chronic Pelvic Pain Syndrome (Urology 2015;85:574-579). Urology. 2015;85(6):1522-3. doi: 10.1016/j.urology.2015.03.023.

7. Pasini M, Kotarski V, Škerk V, Markotić A, Andrašević AT, et al. The signifi cance of Chlamydia trachomatis in prostatitis syndrome. J Chemother. 2014;26(6):382-4. doi: 10.1179/1973947814Y.0000000165

8. Kulchavenya E, Zhukova I, Kholtobin D. Spectrum of Urogenital Tuberculosis. J Infect Chemother. 2013;19(5):880-883. doi: 10.1007/s10156-013-0586-9.

9. Ibishev KhS. Some aspects of the treatment of persistent lower 30 urinary tract infections in women. Urologiya. 2014;(5):30-34. (in Russ.)

10. Zhou M, Yang M, Chen L, Yu C, Zhang W, Ji J, et al. The eff ectiveness of long-needle acupuncture at acupoints BL30 and BL35 for CP/CPPS: a randomized controlled pilot study. BMC Complement Altern Med. 2017;17(1):263. doi: 10.1186/s12906-017-1768-2.

11. He Y, Zeng H, Yu Y, Zhang J, Zeng X, Gong F, et al. Resveratrol improved the progression of chronic prostatis via the downregulation of c-kit/SCF by activating Sirt1. J Agric Food Chem. 2017. doi: 10.1021/acs.jafc.7b01879.

12. Kukushkin ML, Smirnova VS. Anal’geƟ cheskie svoistva protivovirusnogo preparata «Panavir». Rossiiskii zhurnal boli. 2007;1(14):32-36. (in Russ.)

13. Kovchur PI, Bakhlaev IE. Clinical effi ciency of panavir in therapy of chronicle papillomavirus infections of cervix uteri. Vestnik RUDN, seriya Meditsina. 2011;1: 24-28. (in Russ.)

14. Stovbun S, Safronov D, Kucherov V. Panavir: effektivnost’ v regeneraƟ vnoi terapii duodenal’nykh yazv. Vrach. 2011;(10):51-52. (in Russ.)